Photo of Chen Lin from dukecancerinstitute.org
May 29, 2024, 15:16
Chen Lin: Updated results from FELIX for obecabtagene autoleucel in B-ALL by Elias Jabbour et al
Chen Lin, Assistant Professor at Duke Cancer Institute, shared on X/Twitter:
“Updated results from FELIX for obecabtagene autoleucel in B-ALL ASCO Oral 6504:
12months EFS 43%
Only 17% went to allo
Loss of CART persistence = decreased outcomes.
If obe-cel can maintain durable response without allo, would be an impressive feat.”
Source: Chen Lin/X